You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Article info

Article menu
XML
Immune cell therapies and immune cell engineering
IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity

Authors

  • Takayuki Ohkuri Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USABrain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA PubMed articlesGoogle scholar articles
  • Akemi Kosaka Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USABrain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA PubMed articlesGoogle scholar articles
  • Maki Ikeura Brain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USA PubMed articlesGoogle scholar articles
  • Andres M Salazar Oncovir, Inc, Washington, District of Columbia, USA PubMed articlesGoogle scholar articles
  • Hideho Okada Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USABrain Tumor Program, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, PA, USADepartment of Neurological Surgery, University of California San Francisco, San Francisco, California, USAParker Institute for Cancer Immunotherapy, San Francisco, CA, USA PubMed articlesGoogle scholar articles

Citation

Ohkuri T, Kosaka A, Ikeura M, et al
IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity
Journal for ImmunoTherapy of Cancer 2021;9:e002426. doi: 10.1136/jitc-2021-002426
Online issue publication 
February 24, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.